MIC range, MIC50, MIC90 and susceptibility values of cefiderocol and comparators agents tested in 154 CF P. aeruginosa isolates
| Organisms (no. tested)/antimicrobials . | MIC (mg/L) . | EUCAST . | CLSI . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC50 (%) . | MIC90 (%) . | Range . | S (%) . | I (%) . | R (%) . | S (%) . | I (%) . | R (%) . | |
| Cefiderocol | 0.12 | 2 | 0.12–8 | 91.5 | — | 8.5 | 98 | 2 | — |
| Piperacillin/tazobactam | 4 | >64 | 0.5 to >64 | — | 75.3 | 24.7 | 75.3 | 15.5 | 9.2 |
| Ceftazidime | 2 | >64 | 0.25 to >32 | — | 72.7 | 27.3 | 72.7 | 7.1 | 20.2 |
| Ceftazidime/avibactam | 2 | 8 | 0.12 to >8 | 94.1 | — | 5.9 | 94.1 | — | 5.9 |
| Ceftolozane/tazobactam | 1 | 8 | 0.25 to >8 | 86.4 | — | 13.6 | 86.4 | 5.2 | 8.4 |
| Imipenem/relebactam | 0.5 | 4 | 0.06 to >8 | 83.8 | — | 16.2 | 83.8 | 8.4 | 7.8 |
| Meropenem | 0.5 | 16 | 0.06 to >16 | 73.4 | 15.5 | 11.1 | 73.4 | 15.5 | 11.1 |
| Meropenem/vaborbactam | 0.25 | 8 | 0.06 to >8 | 93.5 | — | 6.5 | ND | ND | ND |
| Ciprofloxacin | 2 | 8 | ≤0.03 to >4 | — | 27.9 | 72.1 | 27.9 | 11.7 | 60.4 |
| Colistin | 1 | 2 | 0.12 to >4 | 99.4 | — | 0.6 | — | 99.4 | 0.6 |
| Organisms (no. tested)/antimicrobials . | MIC (mg/L) . | EUCAST . | CLSI . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC50 (%) . | MIC90 (%) . | Range . | S (%) . | I (%) . | R (%) . | S (%) . | I (%) . | R (%) . | |
| Cefiderocol | 0.12 | 2 | 0.12–8 | 91.5 | — | 8.5 | 98 | 2 | — |
| Piperacillin/tazobactam | 4 | >64 | 0.5 to >64 | — | 75.3 | 24.7 | 75.3 | 15.5 | 9.2 |
| Ceftazidime | 2 | >64 | 0.25 to >32 | — | 72.7 | 27.3 | 72.7 | 7.1 | 20.2 |
| Ceftazidime/avibactam | 2 | 8 | 0.12 to >8 | 94.1 | — | 5.9 | 94.1 | — | 5.9 |
| Ceftolozane/tazobactam | 1 | 8 | 0.25 to >8 | 86.4 | — | 13.6 | 86.4 | 5.2 | 8.4 |
| Imipenem/relebactam | 0.5 | 4 | 0.06 to >8 | 83.8 | — | 16.2 | 83.8 | 8.4 | 7.8 |
| Meropenem | 0.5 | 16 | 0.06 to >16 | 73.4 | 15.5 | 11.1 | 73.4 | 15.5 | 11.1 |
| Meropenem/vaborbactam | 0.25 | 8 | 0.06 to >8 | 93.5 | — | 6.5 | ND | ND | ND |
| Ciprofloxacin | 2 | 8 | ≤0.03 to >4 | — | 27.9 | 72.1 | 27.9 | 11.7 | 60.4 |
| Colistin | 1 | 2 | 0.12 to >4 | 99.4 | — | 0.6 | — | 99.4 | 0.6 |
ND, not determined (EUCAST breakpoints have not yet been defined); I, intermediate.
MIC range, MIC50, MIC90 and susceptibility values of cefiderocol and comparators agents tested in 154 CF P. aeruginosa isolates
| Organisms (no. tested)/antimicrobials . | MIC (mg/L) . | EUCAST . | CLSI . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC50 (%) . | MIC90 (%) . | Range . | S (%) . | I (%) . | R (%) . | S (%) . | I (%) . | R (%) . | |
| Cefiderocol | 0.12 | 2 | 0.12–8 | 91.5 | — | 8.5 | 98 | 2 | — |
| Piperacillin/tazobactam | 4 | >64 | 0.5 to >64 | — | 75.3 | 24.7 | 75.3 | 15.5 | 9.2 |
| Ceftazidime | 2 | >64 | 0.25 to >32 | — | 72.7 | 27.3 | 72.7 | 7.1 | 20.2 |
| Ceftazidime/avibactam | 2 | 8 | 0.12 to >8 | 94.1 | — | 5.9 | 94.1 | — | 5.9 |
| Ceftolozane/tazobactam | 1 | 8 | 0.25 to >8 | 86.4 | — | 13.6 | 86.4 | 5.2 | 8.4 |
| Imipenem/relebactam | 0.5 | 4 | 0.06 to >8 | 83.8 | — | 16.2 | 83.8 | 8.4 | 7.8 |
| Meropenem | 0.5 | 16 | 0.06 to >16 | 73.4 | 15.5 | 11.1 | 73.4 | 15.5 | 11.1 |
| Meropenem/vaborbactam | 0.25 | 8 | 0.06 to >8 | 93.5 | — | 6.5 | ND | ND | ND |
| Ciprofloxacin | 2 | 8 | ≤0.03 to >4 | — | 27.9 | 72.1 | 27.9 | 11.7 | 60.4 |
| Colistin | 1 | 2 | 0.12 to >4 | 99.4 | — | 0.6 | — | 99.4 | 0.6 |
| Organisms (no. tested)/antimicrobials . | MIC (mg/L) . | EUCAST . | CLSI . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC50 (%) . | MIC90 (%) . | Range . | S (%) . | I (%) . | R (%) . | S (%) . | I (%) . | R (%) . | |
| Cefiderocol | 0.12 | 2 | 0.12–8 | 91.5 | — | 8.5 | 98 | 2 | — |
| Piperacillin/tazobactam | 4 | >64 | 0.5 to >64 | — | 75.3 | 24.7 | 75.3 | 15.5 | 9.2 |
| Ceftazidime | 2 | >64 | 0.25 to >32 | — | 72.7 | 27.3 | 72.7 | 7.1 | 20.2 |
| Ceftazidime/avibactam | 2 | 8 | 0.12 to >8 | 94.1 | — | 5.9 | 94.1 | — | 5.9 |
| Ceftolozane/tazobactam | 1 | 8 | 0.25 to >8 | 86.4 | — | 13.6 | 86.4 | 5.2 | 8.4 |
| Imipenem/relebactam | 0.5 | 4 | 0.06 to >8 | 83.8 | — | 16.2 | 83.8 | 8.4 | 7.8 |
| Meropenem | 0.5 | 16 | 0.06 to >16 | 73.4 | 15.5 | 11.1 | 73.4 | 15.5 | 11.1 |
| Meropenem/vaborbactam | 0.25 | 8 | 0.06 to >8 | 93.5 | — | 6.5 | ND | ND | ND |
| Ciprofloxacin | 2 | 8 | ≤0.03 to >4 | — | 27.9 | 72.1 | 27.9 | 11.7 | 60.4 |
| Colistin | 1 | 2 | 0.12 to >4 | 99.4 | — | 0.6 | — | 99.4 | 0.6 |
ND, not determined (EUCAST breakpoints have not yet been defined); I, intermediate.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
